Guidelines for Managing Hypercalcemia in Cancer
Guidelines for Managing Hypercalcemia in Cancer
Why It Matters
Following guidelines can make managing hypercalcemia in cancer patients more effective and efficient.
Contents
- Initial Assessment
- Further Diagnostic Tests
- Treatment Approach
Initial Assessment
Start by measuring serum calcium levels to confirm hypercalcemia. Next, check PTH levels to differentiate between primary hyperparathyroidism and other causes. This sets the stage for further testing and management.
Further Diagnostic Tests
If PTH is low, measure PTHrP and vitamin D metabolites. These tests help identify humoral hypercalcemia of malignancy and vitamin D intoxication. Proper diagnosis is crucial for effective treatment.
Treatment Approach
Immediate treatment typically involves hydration and medications like bisphosphonates. These treatments help lower calcium levels and manage symptoms. Long-term treatment plans may vary based on the underlying cause.
FAQs
What is the first step in assessment?
Measure serum calcium levels.
What does low PTH indicate?
It suggests causes other than primary hyperparathyroidism.
Why are bisphosphonates used?
They help lower calcium levels effectively.
Wrapping Up
Adhering to guidelines can lead to better outcomes for cancer patients with hypercalcemia.
Additional References
- Horwitz MJ. Non-parathyroid hypercalcemia. Primer on Metabolic Bone Diseases, 2018.
- Wimalawansa SJ. Significance of plasma PTH-rp in hypercalcemia. Cancer 1994; 73:2223.
This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic.